The move highlights Huawei’s ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical companies are investing in modelling tools and automated laboratories to shorten development timelines and improve efficiency.
“As we further deepen our research into AI in the medical field, we’ll have more collaboration and results emerging with pharmaceutical companies from drug manufacturing to clinical to final implementation,” William Zhang, president of Huawei’s healthcare business unit, said on Wednesday.
He said that Huawei had some existing collaborations in the area of clinical practice in hospitals and was exploring more opportunities.
The projects now are mainly with domestic drugmakers, he said.
US chip giant Nvidia has struck AI-related partnerships with drugmakers such as Eli Lilly and Novo Nordisk, as technology companies seek to capitalise on growing demand for AI-powered drug research.
Huawei offers tools for screening potentially viable drug compounds, alongside its Ascend and Kunpeng chips.
In May, Huawei said one project involving state-owned Guangzhou Pharmaceutical Holdings was the industry’s first production validation of independently developed AI drug research models that were adapted to its Ascend and Kunpeng technologies.
Industry forecasts suggest that the use of machine learning to optimise target discovery, design molecules and streamline clinical trial planning could halve early-stage development timelines and costs within the next three to five years. (Reuters)
